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Objectives. This study was designed to determine the efficacy of 
intravenous amiodarone in the management of recent-onset a rial 
fibrillation. 
Background. The optimal approach for acute atrial fibrillation 
has not been established. Amiodarone is a unique antiarrhythmic 
agent with activity in both supraventricular nd ventricular 
tachyarrhythmias, but its value for the restoration of sinus 
rhythm in patients with recent-onset atrial fibrillation has not 
been demonstrated. 
Methods. Sample size was calculated to detect a25% increase in 
reversion rate with amiodarone with a statistical power of 80%. 
One hundred consecutive patients with recent-onset (<1 week) 
atrial fibrillation and not taking antiarrhythmic agents were 
randomized to receive either intravenous amiodarone, 5 mg/kg 
body weight in 30 min followed by 1,200 mg over 24 h, or an 
identical amount of saline. Both groups received intravenous 
digoxin, 0.5 mg initially, followed by 0.25 mg at 2 h and 0.25 mg 
every 6 h thereafter, to complete 24 h while the ventricular rate 
was > 100 beats/rain. Amiodarone and digoxin blood levels were 
determined. Both groups were homogeneous regarding underlying 
heart disease, time from onset to treatment, initial ventricular 
rate and left atrial size. 
Results. By the end of the 24-h treatment period, 34 patients 
(68%, 95% confidence interval [CI] 53% to 80%) in the amioda- 
rone group and 30 (60%, 95% C145% to 74%) in the control group 
had returned to sinus rhythm (p = 0.532). Mean times (-+SD) of 
conversion were 328 _+ 335 and 332 _+ 359 rain, respectively (p = 
0.957). Among patients who did not convert to sinus rhythm, 
treatment with amiodarone was associated with a slower ventric- 
ular rate (82 -+ 15 beats/min in the amiodarone group vs. 91 -+ 23 
beats/min in the control group, p = 0.022). After restoration 
of sinus rhythm, atrial fibrillation recurred during a 15-day 
follow-up period in 4 (12%) of 34 patients (95% CI 3% to 27%) in 
the amiodarone group and in 3 (10%) of 30 (95% CI 2% to 26%) 
in the control group (p = 0.861). 
Conclusions. Intravenous amiodarone, at the doses used in this 
study, produces a modest but not significant benefit in converting 
acute atrial fibrillation to sinus rhythm. 
(JAm Coil Cardiol 1996;27:1079-82) 
Recent-onset atrial fibrillation is a common occurrence, but its 
treatment is not settled. The pharmacologic approach in the 
acute phase consists of 1) slowing ventricular esponse and 
2) restoring sinus rhythm. Many drugs have been used by the 
intravenous route with both aims. Digoxin (1), calcium antag- 
onists (2) and beta-adrenergic blocking agents (3) slow the 
ventricular response, although they do not convert atrial 
fibrillation to sinus rhythm. The most promising drugs in 
restoration sinus rhythm are the class IC antiarrhythmic drugs 
flecainide and propafenone (4-7). Amiodarone is widely used 
in Europe to revert atrial fibrillation. Its conversion rate has 
been reported to range from 55% to 86% (8-12). Neverthe- 
less, because many patients with atrial fibrillation revert spon- 
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taneously to sinus rhythm, only a randomized, placebo- 
controlled study can establish its real value. 
The purpose of the present study was to determine, in a 
prospective, randomized, single-blind trial, whether intrave- 
nous amiodarone is superior to placebo in converting atrial 
fibrillation of recent onset to sinus rhythm. 
Methods  
Study patients. One hundred consecutive patients (55 
men, 45 women; mean [+SD] age 61 _+ 12 years, range 26 to 
85) with atrial fibrillation of recent onset (<7 days) were 
recruited uring a period of 18 months. All patients were seen 
in the emergency department, on the wards or on the coronary 
unit of our hospital. Confirmatory evidence of the arrhythmia 
was obtained by a 12-lead electrocardiogram in all patients. 
Criteria defining the onset of the arrhythmia included a 
documented onset in patients admitted to the hospital or, for 
those cases seen in the emergency department, an abrupt, well 
defined onset of symptoms, uch as palpitations, chest discom- 
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fort or dyspnea, in patients with no previous history of 
recurrent arrhythmias. 
Exclusion criteria were 1) any previous antiarrhythmic 
treatment (digoxin included); 2) baseline systolic blood 
pressure <100 mm Hg; 3) baseline mean ventricular ate 
<120 beats/min; 4) moderate or severe clinical or radiologic 
signs of congestive heart failure (mild cases were accepted); 5) 
clinical or laboratory data indicative of severe impairment of 
left ventricular function; 6) obstructive hypertrophic cardiomy- 
opathy; 7) renal insufficiency (urea nitrogen >120 mg/dl or 
creatinine >2.5 mg/dl); 8) goiter or thyroid dysfunction; 
9) high degree atrioventricular block; 10) sick sinus syndrome; 
11) pulmonary fibrosis; 12) hepatic dysfunction; and 13) refusal 
to participate. 
Protocol. After informed consent was obtained, patients 
were randomized to receive intravenous amiodarone at the 
dosage of 5 mg/kg body weight over 30 min, diluted in 100 ml 
of saline, followed by 1,200 mg diluted in 500 ml of saline over 
24 h. Patients in the placebo group received an identical 
amount of saline. To reduce the high ventricular ate, both 
amiodarone and placebo groups received intravenous digoxin, 
0.5 mg initially followed by 0.25 mg at 2 h and 0.25 mg every 6 h 
thereafter to complete 24 h (this administration schedule was 
stopped if mean ventricular rate decreased to< 100 beats/min). 
Amiodarone was given by means of an infusion pump 
through either a peripheral vein or a central line. Patients were 
continuously monitored and received subcutaneous calcium 
heparin at a dosage of 2,500 IU/10 kg every 12 h. Intravenous 
infusion containing amiodarone or placebo was interrupted as 
soon as conversion to sinus rhythm was observed. When 
conversion did not occur, the infusion was maintained until the 
completion of 24 h. Blood samples were taken at the end of the 
treatment to determine amiodarone and digoxin blood levels. 
Amiodarone plasma levels were determined by high perfor- 
mance liquid chromatography (13), whereas digoxin serum 
levels were determined by radioimmunoassay. Afterward, pa- 
tients were treated with oral digoxin alone and followed up for 
a 15-day period. 
A Doppler-echoeardiographic recording was performed 
within 72 h of the onset to determine ventricular function, 
atrial size and underlying heart disease. 
Statistics. Statistical analysis was performed using com- 
mercially available software (SPSS PC+/v4.0). The study was 
intended to detect a large, clinically relevant effect of amioda- 
rone. Therefore, sample size was calculated to provide alpha 
and beta probabilities of 0.05 and 0.20, respectively (statistical 
power of 80%) for a 25% increase in the rate of reversion to 
sinus rhythm with amiodarone, assuming a rate of reversion of 
50% in the control group receiving only digoxin. Frequencies 
observed in the two groups of treatment were compared by 
means of the chi-square test. Differences in continuous vari- 
ables were analyzed by means of the t test for independent 
samples. To identify which factors predicted conversion to 
sinus rhythm, patients recovering sinus rhythm were compared 
with patients not recovering sinus rhythm in a univariate 
Table 1. Baseline Patient Data 
Amiodarone Placebo 
(n - 50) (n = 50) 
Age (yr) 60 _+ 13 61 _+ 11 
Male/female 27/23 28/22 
Previous atrial arrhythmias 5 (10%) 7 (14%) 
Duration of AF (h) 25 _+ 32 18 -+ 35 
Cardiac surgery 8 (16%) 9 (18%) 
Heart failure 5 (10%) 6 (12%) 
Ventricular rate (beats/min) 147 -+ 24 141 _+ 24 
Systolic pressure (mm Hg) 138 _+ 25 128 +_ 30 
Left atrial size (mm) 42 _+ 7 42 --+ 8 
LVSF (%) 34 ,+ 7 32 _+ 7 
Cardiac disease/lone atrial 22/28 30/20 
fibrillation 
Data presented are mean value (_+SD) or number (%) of patients. AF = 
atrial fibrillation; LVSF = left ventrieular shortening fraction. 
analysis, and all variables presenting p values <0.10, as well as 
treatment allocation, were included into a stepwise multiple 
logistic regression analysis. A significance leve! of 0.05 was 
used for all comparisons. Continuous variables were expressed 
as mean value + SD. Ninety-five percent confidence intervals 
were calculated for all frequencies by using the binomial 
distribution. 
Resu l ts  
Patient characteristics. Of the 100 patients who were 
randomized, 76 were seen in the emergency department, 18 in 
the coronary unit and 6 in the wards. Regarding underlying 
cardiac disease, 27 patients had valvular, 18 coronary, 5 
cardiomyopathy and 2 miscellaneous heart disease, whereas 48 
patients had idiopathic atrial fibrillation. There were 17 pa- 
tients in whom the arrhythmia occurred uring the postoper- 
ative period after cardiac surgery. Atrial fibrillation was 
present for 21 _+ 34 h (mean _+ SD, range 3 min to 146 h). 
Table 1 shows the baseline data from all patients. There were 
no significant differences between the amiodarone and placebo 
groups regarding age, gender, previous history of atrial ar- 
rhythmias, duration of atrial fibrillation, postoperative period 
of cardiac surgery, mild or moderate heart failure, baseline 
ventricular rate, blood systolic pressure, left atrial size or left 
ventricular shortening fraction by echocardiography. 
Reversion to sinus rhythm. By the end of the 24-h treat- 
ment period, 34 patients (68%, 95% confidence interval [CI] 
53% to 80%) in the amiodarone group had reverted to sinus 
rhythm, whereas 30 patients (60%, 95% C145% to 74%) in the 
control group had reverted (p = 0.532) (Fig. 1). The mean 
times of conversion were 328 _+ 335 and 332 + 359 min, 
respectively (p --- 0.957). At 2, 6 and 12 h 15 (30%), 24 (48%) 
and 28 (56%) patients, respectively, in the amiodarone group 
had converted versus 12 (24%), 23 (46%) and 25 (50%) 
patients, respectively, in the control group (Fig. 1). 
In patients who did not revert o sinus rhythm, ventricular 
rate had decreased at the end of the 24-h period of treatment 
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to 82 _+ 15 beats/min the amiodarone group versus 91 _+ 23 
in the control group (p = 0.022). After restoration of sinus 
rhythm and interruption ofintravenous drugs, atrial fibrillation 
recurred uring a 15-day follow-up in 4 (12%) of 34 patients 
(95% CI 3% to 27%) in the amiodarone group and in 3 (10%) 
of 30 (95% CI 2% to 26%) in the control group (p = 0.861). 
Drug blood levels and side effects. Mean digoxin serum 
levels were 1.21 _+ 0.74 ng/ml in the amiodarone-digoxin group 
and 1.48 + 1.05 in the placebo-digoxin group (p = 0.205). 
Mean amiodarone plasma levels in those patients who received 
the drug were 1.14 _+ 0.97/xg/mt. Digoxin serum concentration 
was not different in patients reverting to sinus rhythm com- 
pared to those not reverting (1.41 _+ 1.06 and 1.22 + 0.57 
ng/ml, respectively, p = 0.302). Similarly, among patients 
receiving amiodarone, plasma levels of this drug were not 
different in those reverting and not reverting to sinus rhythm 
(1.03 + 1.05 and 1.66 _+ 2.57/xg/ml, respectively, p = 0.411). 
Among side effects, hypotension below 100 mm Hg developed 
in four patients in the amiodarone group and in four patients 
in the control group, with good response to volume xpansion 
with saline solution. Medication had to be interrupted in no 
cases. There were one case of nonsustained ventricular tachy- 
cardia and one case of phlebitis in the amiodarone group, and 
two cases of vomiting, one of atrial flutter and one of transient 
junctional rhythm in the control group. 
Predictors of reversion. Patients reverting to sinus rhythm 
differed from those not reverting (Table 2) in that they had 
younger age (p = 0.027), less frequent previous history of 
supraventricular rhythmias (p -- 0.0226), a shorter duration 
of atrial fibrillation from the onset of the arrhythmia to the 
start of the treatment (p = 0.006), smaller left atrial size (p -- 
0.018) and less frequent congestive heart failure (p = 0.00023). 
Multiple logistic regression analysis retained absence of con- 
gestive heart failure (p -- 0.0000), smaller left atrial size (p = 
0.0095) and absence of previous history of supraventricular 
arrhythmias (p -- 0.0191) as independent predictors of conver- 
sion to sinus rhythm, but not treatment allocation (p -- 0.1947). 
Figure 1. Proportion ofpatients who reverted tosinus rhythm (SR) in 
both amiodarone and control groups plotted against time from start of 
infusion. 
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Table 2. Predictors ofReversion (univariate analysis) 
Reversion to SR 
P 
Yes No Value 
Age (yr) 59 -+ 13 64 _+ 10 0.027 
Male 38 (69%) 17 (31%) 
Female 26 (58%) 19 (42%) 0.335 
Baseline heart rate 143 + 22 146 _+ 28 0.590 
(beats/min) 
Baseline SBP 129 -+ 27 140 + 28 0.055 
Baseline DBP 79 -+ 14 85 -+ 83 0.052 
Duration of AF (h) 11.7 -+ 20.8 40.5 _+ 46.3 0.006 
Previous atrial 
arrhythmias 
Yes 5 (42%) 7 (58%) 0.023 
No 59 (67%) 29 (33%) (1 tail) 
Left atrium (mm) 41 + 7 44 _+ 8 0.018 
LVEDD (mm) 53 -+ 7 53 _+ 8 0.852 
LVSF (%) 33 _+ 7 32 _+ 7 0.461 
Heart failure 
Yes 2 (18%) 9 (81%) 
No 61 (77%) 18 (23%) 0.0002 
Cardiac disease 29 (47%) 33 (53%) 
Lone AF 23 (66%) 12 (34%) 0.113 
Data presented are mean value (_+SD) or number (%) of patients. DBP = 
diastolic blood pressure; LVEDD = left ventricular end-diastolic diameter; 
SBP = systolic blood pressure; SR = sinus rhythm. 
Discuss ion  
When acute atrial fibrillation is associated with severe 
hemodynamic deterioration, electrical cardioversion is the 
treatment ofchoice. In a less urgent situation, there is room for 
a less aggressive strategy, and drug therapy can be considered. 
Digitalis is the drug most commonly used. However, as has 
been demonstrated by Falk et al. (1), digitalis does not increase 
the likelihood of reversion, although it helps to control ven- 
tricular rate. Large-scale randomized trials comparing the 
relative benefits of antiarrhythmic drugs have not been re- 
ported, and the optimal approach as not been established. 
The present study was conducted to test the efficacy and safety 
of intravenously administered amiodarone to revert acute 
atrial fibrillation. 
Reversion to sinus rhythm. Amiodarone reverted 68% of 
cases within 24 h, a figure that compares with other uncon- 
trolled trials employing the same drug by intravenous route 
(8-12). However, the control group obtained a not significantly 
different conversion rate of 60%. This latter figure illustrates 
the high spontaneous conversion of recent-onset a rial fibril- 
lation (because digoxin has been shown ineffective in conver- 
sion [1]) and raises some concern as to whether the real 
conversion rate can be attributed to any drug intervention. 
Many factors are involved in the conversion of atrial fibrilla- 
tion, some of which are highlighted by this study, including the 
presence of heart failure, left atrial size, previous history of 
supraventricular rhythmias nd duration of the arrhythmia. 
This explains the differences among series regarding conver- 
sion rates and emphasizes the need for controlled studies. 
1082 GALVE ET AL. JACC Vol. 27, No. 5 
AMIODARONE IN ACUTE ATRIAL FIBRILLATION April 1996:1079-82 
Comparison with other drugs. In reverting acute atrial 
fibrillation, intravenous amiodarone has been demonstrated to 
be superior to verapamil (11) and similar to procainamide (14), 
quinidine (15) and digoxin (16). Regarding class IC agents, 
comparative studies have not demonstrated any statistically 
significant superiority of either propafenone and flecainide 
over amiodarone in conversion rate (17,18). Nevertheless, it 
seems clear that both propafenone and flecainide are faster in 
achieving the conversion to sinus rhythm. In the study by 
Treglia et al. (17), the mean times of conversion for amioda- 
rone and propafenone were 996 and 210 min, respectively (p < 
0.01), and in the study by Capucci et al. (18), the mean times 
of conversion for amiodarone and flecainide were 705 and 
190 min, respectively (p < 0.001). 
Control of ventrieular rate. In cases who did not convert, 
treatment with amiodarone was associated with a significantly 
lower ventricular rate compared with the control group (p = 
0.022). This result could be expected because of the additive 
effects on the atrioventricular node of the two drugs, amioda- 
rone and digoxin. Although fast and effective control of 
ventricular ate is desirable for reducing the symptoms caused 
by the arrhythmia, it is possible that the better control obtained 
with amiodarone could be achieved in a simpler manner by 
increasing the dosage of digoxin. 
Dosage and rate of amiodarone administration. There are 
nearly as many dosages and rates of amiodarone infusion as 
studies in the literature, and none of them has been demon- 
strated to be dearly superior (8,11,12,14,16,17,19). Our trial 
utilized a dose that can be considered adequate at least from 
the point of view of achieving therapeutic levels and control- 
ling ventricular rate, although we cannot rule out that other 
dosages could have obtained other results. Nevertheless, it has 
to be emphasized that higher doses are associated with more 
frequent side effects. 
Study limitations. The differences obtained between the 
amiodarone and the control group in reversion rate (68% vs. 
60%) were not significant, but there was a trend in favor of 
amiodarone (in fact, the amiodarone group had a conversion 
rate 13.3% superior to that of the control group). This raises 
the hypothetical possibility that with a larger sample, this 
difference could reach the significant level. This study was 
designed to detect a clinically relevant effect (>25%) of 
amiodarone in the reversion of acute atrial fibrillation, and the 
results allow us to rule out this effect with reasonably certainty. 
Moreover, a posteriori analysis revealed that the probability of 
obtaining the present results by a type I error in the presence 
of a true beneficial increase of 25% in the reversion rate was 
only 16%. If we consider such other data as the mean time of 
conversion (which was identical for both amiodarone and 
control group) and the number of recurrences of the arrhyth- 
mia (slightly superior in the amiodarone group), the present 
results allow us to conclude that amiodarone is of little if any 
help in the management of acute atrial fibrillation. 
Re ferences  
1. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for 
converting recent-onset a rial fibrillation to sinus rhythm: a randomized 
double-blind trial. Ann Intern Med 1987;106:503-6. 
2. Singh B, Nademanee K. Use of calcium antagonists for cardiac arrhythmias. 
Am J Cardiol 1987;59:153B-62B. 
3. Coumel PH, Leclercq JF, Escoubet B. Beta blockers: use for arrhythmias. 
Eur Heart J 1987;8: Suppl A:41-52. 
4. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effective- 
ness of intravenous propafenone for conversion of atrial fibrillation and 
flutter of recent onset. Am J Cardiol 1989;64:335-8. 
5. Donovan KD, Dobb GJ, Coombs LJ, et al. Reversion of recent-onset a rial 
fibrillation to sinus rhythm by intravenous flecainide. Am J Cardiol 1991;67: 
137-41. 
6. Capucci A, Boriani G, Rubino I, Della-Casa S, Sanguinetti M, Magnani B. 
A controlled study on oral propafenone versus digoxin plus quinidine in 
converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 
1994;43:305-13. 
7. Weiner P, Ganam R, Ganem R, Zidan F, Rabncr M. Clinical course of 
recent-onset a rial fibrillation treated with oral propafenone. Chest 1994; 
105:1013-6. 
8. Installe E, Schoevaerdts JC, Gadisseux P, Charles S, Trcmouroux J. Intra- 
venous amiodarone in the treatment of various arrhythmias following 
cardiac operations. J Thorac Cardiovasc Surg 1981;81:302-8. 
9. Faniel R, Schoenfeld P. Efficacy of i.v. amiodarone inconverting rapid atrial 
fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart 
J 1983;4:180-5. 
10. Strasberg B, Arditti A, Sdarovsky S, Lewin RF, Buimovici B, Agmon J. 
Efficacy of intravenous amiodarone in the management of paroxysmal or 
new atrial fibrillation with fast ventricular response, lnt J Cardiol 1985;7:47- 
55. 
11. Noc M, Stajer D, Horvat M. Intravenous amiodarone versus verapamil for 
acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am J 
Cardiol 1990;65:679-80. 
12. Vietti-Ramus G, Veglio F, Marchisio U, Burzio P, Latini R. Efficacy and 
safety of short intravenous amiodarone in supraventricular t chyarrhyth- 
mias. Int J Cardiol 1992;35:77-85. 
13. Debbas N, Du Cailar C, Sassine A, Derancourt J, Demaille J, Puech P. 
Determination of cardiac and plasma drug levels during long term amioda- 
rone therapy. Eur J Clin Pharmacol 1983;13:69-81. 
14. Chapman MJ, Moran JL, O'Fathartaigh MS, Peisach AR, Cunningham DN. 
Management of atrial tachyarrhythmias in the critically ill: a comparison of 
intravenous procainamide and amiodarone. Intensive Care Med 1993;19:48- 
52. 
15. Negrini M, Gibelli G, De Ponti C. Comparison of amiodarone and quinidine 
in the conversion of recent-onset a rial fibrillation to sinus rhythm. G Ital 
Cardiol 1990;20:207-14. 
16. Cochrane AD, Siddins M, Rosenfeldt FL, et al. A comparison ofamiodarone 
and digoxin for treatment of supraventricular rrhythmias after cardiac 
surgery. Eur J Cardiothorac Surg 1994;8:194-8. 
17. Treglia A, Alfano C, Rossini E. A comparison between propafenone and 
amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent 
onset. Minerva Cardioangiol 1994;42:293-7. 
18. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide 
for converting recent-onset a rial fibrillation to sinus rhythm in patients 
without organic heart disease or with only systemic hypertension. Am J 
Cardiol 1992;70:69-72. 
19. Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and 
antiarrhythmic effects of intravenous amiodarone: results of a prospective, 
placebo-controlled study. Am Heart J 1991;121:89-95. 
